Amgen Inc

More Details of Amgen Inc Company

Company Info

Company codeAMGN

Company nameAmgen Inc

IPO dateJun 17, 1983

Founded at1986

CEOMr. Robert A. (Bob) Bradway

Number of employees28000

Security typeOrdinary Share

Fiscal year-endJun 17

AddressOne Amgen Center Drive

CityTHOUSAND OAKS

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code91320-1799

Phone18054471000

Websitehttps://www.amgen.com/

Company codeAMGN

IPO dateJun 17, 1983

Founded at1986

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

454.47K

-29.04%

Mr. Esteban Santos

Executive Vice President - Operations

64.35K

--

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

34.80K

-20.13%

Dr. Tyler Jacks

Independent Director

16.00K

+4.70%

Mr. Derek Miller

Senior Vice President of Human Resources

8.31K

-5.67%

Ms. Rachna Khosla

Senior Vice President - Business Development

8.04K

-2.57%

Dr. Brian J. Druker, M.D.

Independent Director

6.59K

+12.23%

Dr. Wanda M. Austin, Ph.D.

Independent Director

6.54K

+12.34%

Ms. Nancy A. Grygiel

Senior Vice President, Chief Compliance Officer

6.07K

-20.73%

Ms. Amy E. Miles

Independent Director

3.92K

+22.41%

Name

Name/Position

Position

Shareholding

Change

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

454.47K

-29.04%

Mr. Esteban Santos

Executive Vice President - Operations

64.35K

--

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

34.80K

-20.13%

Dr. Tyler Jacks

Independent Director

16.00K

+4.70%

Mr. Derek Miller

Senior Vice President of Human Resources

8.31K

-5.67%

Ms. Rachna Khosla

Senior Vice President - Business Development

8.04K

-2.57%

Revenue Breakdown

Currency: USDUpdate time: Wed, Mar 5

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Other products

5.63B

16.84%

Prolia

4.37B

13.08%

Enbrel

3.31B

9.92%

XGEVA

2.22B

6.65%

Repatha

2.22B

6.64%

Other

15.65B

46.84%

By RegionUSD

Name

Revenue

Proportion

US

23.30B

69.71%

ROW

8.72B

26.10%

Other revenues

1.39B

4.18%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Other products

5.63B

16.84%

Prolia

4.37B

13.08%

Enbrel

3.31B

9.92%

XGEVA

2.22B

6.65%

Repatha

2.22B

6.64%

Other

15.65B

46.84%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.77%

State Street Global Advisors (US)

5.47%

BlackRock Institutional Trust Company, N.A.

5.35%

Charles Schwab Investment Management, Inc.

2.45%

PRIMECAP Management Company

2.42%

Other

74.51%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.77%

State Street Global Advisors (US)

5.47%

BlackRock Institutional Trust Company, N.A.

5.35%

Charles Schwab Investment Management, Inc.

2.45%

PRIMECAP Management Company

2.42%

Other

74.51%

Type

Shareholder

Proportion

Investment Advisor

40.29%

Investment Advisor/Hedge Fund

29.71%

Research Firm

4.21%

Pension Fund

2.23%

Bank and Trust

2.05%

Hedge Fund

1.61%

Sovereign Wealth Fund

1.21%

Insurance Company

0.57%

Holding Company

0.31%

Other

17.75%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

4351

442.51M

82.37%

+143.62K

2024Q4

4466

443.40M

82.54%

+89.77K

2024Q3

4316

438.01M

81.42%

-5.12M

2024Q2

4284

437.79M

81.61%

-4.93M

2024Q1

4192

436.24M

81.40%

-5.10M

2023Q4

4150

435.28M

81.36%

+42.25K

2023Q3

3990

429.94M

80.36%

-4.48M

2023Q2

3936

426.14M

79.65%

-4.33M

2023Q1

3951

427.28M

80.00%

-4.35M

2022Q4

3946

428.59M

80.25%

-5.45M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

52.48M

9.77%

+346.49K

+0.66%

Dec 31, 2024

State Street Global Advisors (US)

29.43M

5.47%

+117.39K

+0.40%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

28.79M

5.35%

+444.90K

+1.56%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

13.20M

2.45%

+2.67M

+25.37%

Dec 31, 2024

PRIMECAP Management Company

13.00M

2.42%

-1.25M

-8.79%

Dec 31, 2024

Geode Capital Management, L.L.C.

12.47M

2.32%

+352.14K

+2.90%

Dec 31, 2024

Capital International Investors

12.21M

2.27%

+3.49M

+40.10%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

10.90M

2.02%

+219.85K

+2.05%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

8.37M

1.55%

-185.42K

-2.16%

Dec 31, 2024

Wells Fargo Advisors

6.91M

1.28%

-231.47K

-3.23%

Dec 31, 2024

Related ETFs

Update time: 13 hours ago

Name

Proportion

VanEck Biotech ETF

16.38%

ProShares Ultra Nasdaq Biotechnology

8.56%

Invesco Nasdaq Biotechnology ETF

8.1%

iShares Biotechnology ETF

7%

Proshares UltraPro Dow 30

5.68%

Amplify CWP Enhanced Dividend Income ETF

5.25%

FT Vest DJIA Dogs 10 Target Income ETF

4.84%

Invesco Biotechnology & Genome ETF

4.71%

Invesco Pharmaceuticals ETF

4.63%

Global X Dow 30 Covered Call ETF

4.55%

VanEck Biotech ETF

Proportion16.38%

ProShares Ultra Nasdaq Biotechnology

Proportion8.56%

Invesco Nasdaq Biotechnology ETF

Proportion8.1%

iShares Biotechnology ETF

Proportion7%

Proshares UltraPro Dow 30

Proportion5.68%

Amplify CWP Enhanced Dividend Income ETF

Proportion5.25%

FT Vest DJIA Dogs 10 Target Income ETF

Proportion4.84%

Invesco Biotechnology & Genome ETF

Proportion4.71%

Invesco Pharmaceuticals ETF

Proportion4.63%

Global X Dow 30 Covered Call ETF

Proportion4.55%

Dividend

A total of 21.35B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Dec 10, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 07, 2025

Feb 14, 2025

Oct 25, 2024

AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024

Nov 18, 2024

Dec 09, 2024

Nov 18, 2024

Aug 02, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 06, 2024

Aug 16, 2024

Mar 06, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024

May 17, 2024

Jun 07, 2024

May 16, 2024

Dec 12, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024

Feb 16, 2024

Mar 07, 2024

Feb 15, 2024

Oct 24, 2023

AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023

Nov 17, 2023

Dec 08, 2023

Nov 16, 2023

Aug 01, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 08, 2023

Aug 17, 2023

Mar 07, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023

May 18, 2023

Jun 08, 2023

May 17, 2023

Dec 12, 2022

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023

Feb 15, 2023

Mar 08, 2023

Feb 14, 2023

Oct 28, 2022

AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022

Nov 17, 2022

Dec 08, 2022

Nov 16, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

316.570USD

Amgen Inc

316.570

Overview

Company